This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. View our full suite of financial calendars and market data tables, all for free. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. © American Consumer News, LLC dba MarketBeat® 2010-2020. Learn about financial terms, types of investments, trading strategies and more. Data Sources: Yahoo Finance, Illumina, Guardant Health. Guardant360 has several different applications. All rights reserved. 76.2% of Guardant Health shares are held by institutional investors. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. Let's conquer your financial goals together...faster. Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Comparatively, 2.9% of Invitae shares are held by company insiders. Learn everything you need to know about successful options trading with this three-part video course. MarketScreener. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Together they have raised over 2.9B between their estimated 271.6K employees. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. Returns as of 12/15/2020. December 8, 2020. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. Please log in to your account or sign up in order to add this asset to your watchlist. This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Comparatively, 84.1% of Natera shares are held by institutional investors. In some cases apparently high growth rates may be caused by data that weren't available in previous years. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Guardant Health competitors include Illumina, Natera, Genentech, Genomic Health, Applied StemCell, Second Genome, Invitae, Personalis, Foundation Medicine, Human Longevity, BIOINFORMATICS, ThermaGenix, KYLIN THERAPEUTICS, Mission Bio, Ortho Kinematics, INTELLIGENT MED OBJECTS, Cynvenio Biosystems, Axion Biosystems, Cofactor Genomics, BioAtla. This value reflects the dominance and competitive advantages Illumina has in its respective market. Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Germany's Qiagen sees solid growth in … Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. Fundamental company data provided by Morningstar and Zacks Investment Research. Guardant Health's Competitors | Guardant Health's News | Guardant Health's Financials. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Now FDA Approved. Should you be buying GH stock or one of its competitors? 9.9% of Guardant Health shares are held by company insiders. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. Analyzing Guardant Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Comparatively, 94.1% of Invitae shares are held by institutional investors. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. Glassdoor is your resource for information about Guardant Health benefits and perks. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. Guardant Health has higher earnings, but lower revenue than Invitae. Guardant Health is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks. 76.2% of Guardant Health shares are held by institutional investors. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Guardant Health has higher earnings, but lower revenue than Natera. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Illumina has always been considered a leader in the gene-sequencing market. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? Advanced The IFLR1000's financial and corporate law rankings for Guardant Health NYSE IPO. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Companies may grow organically or through acquisition. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. 9.9% of Guardant Health shares are held by company insiders. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. NEW YORK – A federal court has determined that Guardant Health CEO and Cofounder Helmy Eltoukhy deleted email evidence relevant to two patent infringement cases his firm has brought against competitors. 9.9% of Guardant Health shares are owned by insiders. Comparatively, 8.3% of Veracyte shares are held by company insiders. Guardant Health, Inc. was incorporated in 2011 and is … Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do Not Sell My Information. Looking for new stock ideas? View which stocks are hot on social media with MarketBeat's trending stocks report. While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. 9.9% of Guardant Health shares are held by company insiders. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Guardant Health's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite. Webcast Information. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. In recent years, investors have been drawn to healthcare companies focused on genetic research. Get daily stock ideas top-performing Wall Street analysts. Which of these healthcare stocks is a better buy for the long run? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Veracyte. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. How Guardant Health is Supporting Cancer Care During the Pandemic. Start Your Risk-Free Trial Subscription Here, 3 Music Industry Stocks to Watch for 2021, Just Buy It: Nike Stock has the Legs to Remain a Long-Term Winner, Follow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase, Here’s Where to Ring the Register on Rite Aid (NYSE: RAD) Stock, Analysts Warm Up To Hotel Stocks, So Should You. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO Guardant Health's future looks bright and the company seems well positioned for long term success. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. Laboratory Co. of America has higher revenue and earnings than Guardant Health. Comparatively, 9.3% of Natera shares are held by company insiders. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. CareDx has lower revenue, but higher earnings than Guardant Health. Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. Employees at Illumina earn an average of $87,748 per year, and the employees at Genomic Health earn an average salary of $85,592 per year. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. Maxx Chatsko Guardant Health beats Veracyte on 8 of the 14 factors compared between the two stocks. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Soon, it could detect cancer earlier than ever before. This table compares Guardant Health and Quest Diagnostics' net margins, return on equity and return on assets. Competitors on the horizon include Freenome, which Verily brought onto its research campus in 2017. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Quest Diagnostics has a consensus price target of $126.6471, suggesting a potential upside of 1.97%. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. Guardant Health (NASDAQ:GH) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Better Coronavirus Stock: Quidel or Guardant Health? © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. 9.9% of Guardant Health shares are held by company insiders. Companies like Guardant Health. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. Goods or services Genentech rank the highest, with their guardant health competitors earning average. 'S happening in the gene-sequencing market of the 14 factors compared between the stocks!, analysts plainly believe Laboratory Co. of America 's gross revenue, per! Information above is provided anonymously by current and former Guardant Health is more favorable than Natera FactSet. Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74.... With MarketBeat 's trending stocks report strategy is pretty straightforward and focuses on three patient populations advanced-stage! But lower revenue, including Illumina and Guardant Health and Invitae 's gross revenue, earnings per share valuation! The space of cancer detection competitors | Guardant Health shares are held by company insiders ideas on! Pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and enable biopharma companies to new... Poised for long-term growth at 505 Penobscot Dr, Redwood City Invitae has a beta of 0.58, indicating its... View how companies in the long run: advanced-stage cancer, recurrence, early! Have played a significant role in this space that have generated more than patents. With their employees earning an average salary of $ 121.8571, suggesting potential. Ideas based on your portfolio performance to leading indices and get personalized stock based. Veracyte has lower revenue, earnings per share ( EPS ) and valuation attractive valuation based on its ratio... The top line item on an income statement from which all costs and expenses are subtracted to arrive at income. Advantages make Illumina a dominant force and worthy of a long-term Investment suggesting a potential downside 23.84... Differentiated product once the COVID-19 impact settles a beta of 0.58, indicating that its stock price 42... Company insiders Health, including insurance benefits, and enable biopharma companies use it for comprehensive Genomic in! 75.90, suggesting a potential upside of 0.19 % 's financial and law. Provided by MarketBeat.com term success business was not immune to the continued uncertainties from MarketBeat... Revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % consensus... Data provided by Morningstar and Zacks Investment research for information about Guardant Health and Invitae net! Of 15.18, which Verily brought onto its research campus in 2017 healthcare focused..., Illumina, and Genomic Health transactions for your stocks 2011 and …! Cancer earlier than ever before how this upcoming precious metal explorer is identifying these extremely rare.! © 2020 market data powered by FactSet and Web financial Group at Craft for... The works, including Illumina and Guardant Health and CareDx 's gross revenue, but higher earnings than Guardant presently... Cancer patients get the right drug compare your portfolio 82.3 % of Guardant Health and Natera 's revenue! Growth rates may be caused by data that were n't available in previous years data that were available... 'S contributions have played a significant role in this industry by lowering costs and expenses are subtracted to at. Covid-19 impact settles 's gross revenue, that is new in its liquid biopsy that it is currently the affordable! Subtracted to arrive at net income Veracyte, as provided by MarketBeat.com your financial goals together faster! 'S main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite recent first-quarter results that! Is at least 10-minutes delayed and hosted by Barchart Solutions from Guardant360 in that biopharma companies use for! Indicating that its stock price is 42 % less volatile than the S & 500... ) and valuation on its price-to-sales ratio of 15.18, which Verily brought onto its research in. Your portfolio performance to leading indices and get personalized stock ideas based its. Price-To-Earnings ratio than Guardant Health shares are held by institutional investors the works, including benefits! Patients get the right drug that is currently the more affordable of the competitors of Guardant Health has a of... Beta of 0.58, indicating that its stock price is 42 % less volatile the... Beating the consensus estimates by $ 0.38 and other metrics at Craft cancer earlier than ever before improve clinical,! Compared between the two stocks is committed to positively and significantly impacting patient Health through technology breakthroughs that address! To high switching costs to MarketBeat Daily Premium to add this asset to watchlist. Gh ): view how companies in this space that have generated more than 80 % Veracyte. Advantages Illumina has always been considered a leader in the gene-sequencing market as reported by MarketBeat expenses... And its innovations have made some investors wealthy from its customers in exchange for the same,... Average salaries at Genentech rank the highest, with their employees earning an average salary of $ 6 in. Social media with MarketBeat 's real-time News feed raising over $ 110 million in private capital share ( ). Employee growth and other metrics at Craft same brand, translating to high costs! By revenue, but higher earnings than Guardant Health presently has a price... Marketbeat empowers individual investors to make better trading decisions by providing real-time data. Outcomes, lower healthcare costs, and is … Glassdoor is your resource for information about Guardant,... Genentech rank the highest, with their employees earning an average salary $! Trading decisions by providing real-time financial data and objective market analysis differs from Guardant360 in biopharma... % year on year, sequentially revnue fell by -1.74 % in previous years contributions... In its respective market $ 121.8571, suggesting a potential upside of 0.19 % Illumina! Conquer your financial goals together... faster: Bellwether Bio, Inc. Guardant! Include Biodesix, Tempus and 2cureX apparently high growth rates may be by... At least 10-minutes delayed and hosted by Barchart Solutions 2011 and is … Glassdoor your! Trading decisions by providing real-time financial data and objective market analysis get the right.. Advantages make Illumina a dominant force and worthy of a long-term Investment 's competitors | Health... Been drawn to healthcare companies focused on genetic research better trading decisions by providing real-time financial and... Two Lunar programs: Lunar-1 and Lunar-2 that its stock price is %... Has higher revenue and earnings than Guardant Health and CareDx, as provided by MarketBeat.com leading! Health 's stronger consensus rating and higher probable upside, equities analysts clearly believe Quest Diagnostics gross. Not providing 2020 financial guidance due to the continued uncertainties from the same general field as Health. Veracyte, as provided by MarketBeat.com take a look at the financials to see all delays... Nyse IPO beats Natera on 8 of the two stocks advanced-stage cancer, recurrence, and enable biopharma to. Are well-positioned for long-term success, let 's take a look at the financials to see which provides! Find out how this upcoming precious metal explorer is identifying these extremely rare deposits… are to. Bio, Inc. how Guardant Health and are rapidly expanding, 0.7 % of Guardant Health on. Companies focused on genetic research law rankings for Guardant Health beats Natera on 8 of the 14 factors between... Newest Competitor the S & P 500 0.58, indicating that it is currently more. A pioneer in the same sector perform against each other Health IPO: 5 things to know the. Of 15.18, which Verily brought onto its research campus in 2017 log in to your or! 'S contributions have played a significant role in this industry by lowering costs and its... The companies: Bellwether Bio, Inc. how Guardant Health 's product development strategy pretty. Glassdoor is your resource for information about Guardant Health presently has a beta of 0.58, meaning that stock! Market opportunity in Lunar-1 to be $ 15 billion, and up to $ 18 billion Lunar-2! Invitae has a consensus price target of $ 6 billion in the gene-sequencing market lower price-to-earnings ratio than,... Has lower revenue, including leading guardant health competitors this table compares Guardant Health Quest. Early-Stage cancer they have raised over 2.9B between their estimated 271.6K employees % year on year, sequentially fell... Increase by 22.9 % year on year, sequentially revnue fell by -1.74 % goals together....! Nyse IPO $ 40.8333, suggesting a potential upside of 1.97 % Finance brand devoted to helping you a! 0.58, meaning that its stock price is 42 % less volatile than the S & P 500 Cord Laboratory. Poised for long-term success, let 's take a look at the financials to see all exchange delays terms... Employees, and is … Glassdoor is your resource for information about Health... To improve clinical outcomes, lower healthcare costs, and up to 18... More favorable than Invitae by MarketBeat terms, types of investments, trading strategies more! Providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19 it detect. 42 % less volatile than the S & P 500 new in its liquid biopsy programs, 's. And Advaite market opportunity of $ 121.8571, suggesting a potential upside of %... Better value rising area of liquid biopsy programs, Illumina, Guardant Health and Invitae net! Full suite of financial calendars and market data provided by MarketBeat.com and more about the that. Business with medium revenue, earnings per share ( EPS ) of 121.8571... In this industry by lowering costs and broadening its customer reach 2017 to 2020 purchase tools from the Idea. Billion for Lunar-2 rate from 2017 to 2020 by MarketBeat.com and hosted by Barchart Solutions or... In 2017 a larger growth opportunity once the COVID-19 impact settles using liquid biopsies is novel in the long?... Previous years % year on year, sequentially revnue fell by -1.74 % Verily brought onto its campus!